Navigation Links
Ruthigen Reports Fiscal First Quarter 2015 Financial Results
Date:8/14/2014

the call.

About Ruthigen
Ruthigen is a biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics designed to prevent and treat infection in invasive applications.  The Company's lead drug candidate, RUT58-60, is a broad-spectrum anti-infective that Ruthigen is developing for the prevention and treatment of infection in surgical and trauma procedures.  The Company plans to complete its Phase 1/2 clinical trial in the first calendar quarter of 2015 and pending the successful completion of that trial, Ruthigen plans to conduct pivotal clinical trials.  For more information, visit www.ruthigen.com.

About RUT58-60
RUT58-60 is a new chemical formulation containing hypochlorous acid, HOCl, with no hypochlorite, and utilizes other small molecule stabilizers.  RUT58-60 is a broad-spectrum anti-infective drug candidate designed for prophylactic use during invasive surgical procedures. RUT58-60 has been shown in laboratory tests to eradicate both gram-positive and gram-negative bacteria, including antibiotic resistant bacteria within the first 30 seconds of contact.  RUT58-60 was designed to improve patient lives, redefine infection control in surgical procedures and deliver cost savings to hospitals.  RUT58-60 uses a mechanism of action designed to prevent emergence of bacterial resistance and improves patient safety by neither targeting specific bacterial cell membrane receptors nor exposing patient's vital organs to unnecessary systemic drugs.  The Company's clinical program targets an initial $700M potential market in the prevention of infections associated with abdominal surgery.  The Company believes the market for prevention of infection in the U.S. surgical market is estimated at $3B. 

Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and un
'/>"/>

SOURCE Ruthigen, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Ruthigen Treats First Human Subjects In Clinical Trial For RUT58-60
2. Perrigo Company plc Reports Record Fourth Quarter And Fiscal Year Revenue, Adjusted Operating Income And Adjusted Margins. Conference call scheduled for 10 a.m. ET today.
3. Perrigo Company plc Reports Record Fourth Quarter And Fiscal Year Revenue, Adjusted Operating Income And Adjusted Margins
4. CASI Pharmaceuticals Reports Second Quarter 2014 Financial Results
5. VirtualScopics, Inc. Reports Second Quarter and Six Months 2014 Financial Results; Awards Outstanding and Bookings Reflect a Two-Fold Increase Over 2013 First Six Months
6. PDI Reports 2014 Second Quarter Financial Results
7. Dipexium Pharmaceuticals Reports Second Quarter 2014 Financial and Operational Results
8. Organovo Highlights Liver Toxicology Achievement, Reports Q1 Fiscal 2015 Results
9. Egalet Reports Second Quarter 2014 Financial Results and Provides Business Update
10. Aratana Therapeutics Reports Second Quarter 2014 Results
11. Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2014
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... Inc. (NASDAQ: VRML ), a bio-analytical solutions company ... the 27 th Annual ROTH Conference, which is being ... from March 8 to March 11. ... will be presenting on Monday, March 9 at 12:00 noon ... the company,s Vice President of Finance and Chief Accounting Officer. ...
(Date:3/3/2015)... 03, 2015 Research and Markets ( ... "Blister Packaging Market in the US 2015-2019" report ... market in the US to grow at a CAGR ... is a form of high-visibility packaging that uses pre-formed ... packs comprise a base layer, made either of plastic ...
(Date:3/3/2015)... 2015  BioPharmX Corporation (OTCQB: BPMX), a specialty pharmaceutical ... products to address unmet needs in large, well-defined and ... chief executive officer and co-founder of BioPharmX, will present ... Conference on Wednesday, March 11 at 9:00 a.m. PDT ... in Dana Point , California.   ...
Breaking Medicine Technology:Vermillion To Present at 27th Annual ROTH Conference on March 9 2United States Blister Packaging Market 2015-2019 - Growing Demand in Pharmaceuticals Industry with Amcor, Bemis, MeadWestvaco & Sonoco Products Dominating 2BioPharmX Corporation To Present At 27th Annual Roth Capital Partners Conference On March 11, 2015 2BioPharmX Corporation To Present At 27th Annual Roth Capital Partners Conference On March 11, 2015 3
... Medicated Arthri-Zen Relief Cream(R) Clinically Shown to Work for up ... Americans suffer from the aches and pains that come with ... effective ways to get fast relief from arthritis pain is ... the relief tends to be short-lived. Many people find that ...
... economic slowdown, America,s pharmaceutical research and biotechnology companies ... the research and development of new life-changing medicines ... billion from 2007, according to analyses by the ... Burrill & Company. PhRMA-member companies alone invested ...
Cached Medicine Technology:Fast-Acting, Long-Lasting Topical Relief From Arthritis Pain 2Fast-Acting, Long-Lasting Topical Relief From Arthritis Pain 3R&D Spending by U.S. Biopharmaceutical Companies Reaches Record Levels in 2008 Despite Economic Challenges 2R&D Spending by U.S. Biopharmaceutical Companies Reaches Record Levels in 2008 Despite Economic Challenges 3R&D Spending by U.S. Biopharmaceutical Companies Reaches Record Levels in 2008 Despite Economic Challenges 4
(Date:3/4/2015)... 04, 2015 i2i Systems Population ... by Chase Brexton Health Care, a 35-year-old Maryland-based ... Chase Brexton provides comprehensive primary care, behavioral health ... across seven clinics in the greater Baltimore area ... medical records, the organization has always focused on ...
(Date:3/4/2015)... 2015 Dietary supplement company MitoSynergy ... first biocompatible copper chelate, at Natural Products Expo West ... chance to gain insight into their wellness through a ... complex can support their individual nutritional needs, all while ... the core ingredient of the MitoSynergy product line, was ...
(Date:3/4/2015)... Dallas, TX (PRWEB) March 04, 2015 ... comprehensive information on the therapeutic development for Vasculitis. Vasculitis ... vessels. The actual cause of vasculitis diseases is not ... have a wide range of symptoms. Symptoms can include ... and loss of a pulse in a limb. Vasculitis ...
(Date:3/4/2015)... TheraBreath is proud to announce a new probiotic lozenge ... with overall health. , Many health experts agree that ... bad bacteria that can cause unwanted infections. While most people ... will need the help of a probiotic to elevate the ... Packed with the S. salivarius M18 & K12 strains of ...
(Date:3/4/2015)... 2015 Theme and plugin developers from ... for Final Cut Pro X entitled ProFont NoteBook , “ProFont ... any FCPX editors project.” Said Christiana Austin, CEO of Pixel ... add animated font to their FCPX media.” , With ProFont ... within Final Cut Pro X. ProFont Notebook offers users up ...
Breaking Medicine News(10 mins):Health News:Chase Brexton Selects i2i Systems Population Health Management Solutions to Demonstrate HEDIS Quality Outcomes to Maryland’s Health Plans 2Health News:Chase Brexton Selects i2i Systems Population Health Management Solutions to Demonstrate HEDIS Quality Outcomes to Maryland’s Health Plans 3Health News:MitoSynergy Invites Expo West Attendees to Sit Back, Relax and Take Time for Their Health 2Health News:Vasculitis Therapeutics Pipeline H1 2015 Review Report Available at RnRMarketResearch.com 2Health News:Vasculitis Therapeutics Pipeline H1 2015 Review Report Available at RnRMarketResearch.com 3Health News:Vasculitis Therapeutics Pipeline H1 2015 Review Report Available at RnRMarketResearch.com 4Health News:TheraBreath introduces a new line of probiotic lozenges that strengthen the body’s ability to fight germs 2Health News:Announcing a New Title Pack from Pixel Film Studios, ProFont NoteBook for Final Cut Pro X 2
... where endometrial tissue, which is normally found only in ... // and attaches itself to ligaments and organs in ... include pain, bleeding, inflammation, adhesions and infertility. ... with endometriosis are at higher risk of having migraines. ...
... be a strong link between Skin Allergies and cancer. People who ... blood related caners as they grow older. A Swedish team of ... of the BMC public Health. ,In this alarming finding ... likely to develop Leukemia and those of us who have ...
... studying around 700,000 people researchers say dads who have ... risk // for developing schizophrenia later in life. ... admitted to the hospital in Sweden between 1989 and ... psychosis. Researchers say they found a strong association between ...
... samples for viral RNA among organ and tissue donors who ... // transmission among transplant recipients, say researchers according to a ... diseases such as HIV or hepatitis C is the usual ... may be infected with a virus but show a full ...
... suffer from sleep apnea run a higher risk of complications ... apnea is a condition in which patients stop breathing periodically ... the condition, known as obstructive sleep apnea, affects as many ... of all middle-aged women. ,Researchers say 80 percent of ...
... to gain complete control of their condition, say researchers ... uncontrolled asthma. Some of the patients had never before ... on a low-dose inhaled steroid; and some were on ... were randomly assigned to receive either the inhaled steroid ...
Cached Medicine News:
Test for determination of rheumatoid factor....
... The SYNCHRON CX4 Delta Specialty / ... access analyzer that can consolidate Drugs ... testing, such as thyroid, HbA1c and ... CX4 Delta offers a level of ...
The Rheumatoid Factor (RF) assay is used for the quantitative analysis of rheumatoid factor in human serum....
Rheumatoid Factor , R1: 4 X 20 ml buffer, R2: 2 X 8 ml antibody, Test / Kit: 320 (H717)...
Medicine Products: